PAA 2.50% 20.5¢ pharmaust limited

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1139

  1. 8,913 Posts.
    lightbulb Created with Sketch. 1726
    Lastly
    Did the phase 2b canine trial meet the main end point (target).
    The answer is no it did not so my statement that it failed to meet its target end point is correct so who are by saying my statement is false
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.